Daniel Gerardi, MD
Pulmonary Disease · Hartford, CTNPI 1538167424
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), other and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Alcon at 34.8% of the total. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $961.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$54K
- AstraZeneca$54K
- GSK$37K
- Amgen$5K
- Intuitive Surgical$4K
- Viiv Healthcare Company$600
- plus $698 from 4 others
What the payments were for
- Consulting fees$3450%
- Speaking & faculty fees$90,66558%
- Travel & lodging$1,6651%
- Food & beverage$5,8654%
- Education$3,0012%
- Other$54,28235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 2 | $54,282 |
| AstraZeneca | 77 | $54,264 |
| GSK | 47 | $37,223 |
| Amgen | 8 | $4,899 |
| Intuitive Surgical | 17 | $3,857 |
| Viiv Healthcare Company | 1 | $600 |
| Biomerieux Inc | 1 | $345 |
| Inspire Medical Systems, Inc. | 2 | $144 |
| Covidien LP | 3 | $141 |
| Medtronic | 4 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$31,427
- FASENRA$30,235
- TEZSPIRE$23,301
- ANORO$5,042
- ION$3,000
- NephroCheck Test Kit$345
- Inspire$125
- Da Vinci Surgical System$119
- superDimension$119
- ANORO ELLIPTA$109
How this compares
$155,822 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 68 | $938,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 556 | $542,675 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 194 | $181,621 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 225 | $166,111 |
| Fasenra PenBenralizumab | 21 | $137,280 |
| Breo ElliptaFluticasone/Vilanterol | 192 | $115,919 |
| Ambrisentan | 24 | $58,771 |
| Pirfenidone | 27 | $46,983 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $28,191 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $23,236 |
| EliquisApixaban | 14 | $15,033 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,867 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 29 | $13,252 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 18 | $9,838 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $8,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $37,223 | $833,287989 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $54,264 | $223,064298 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Jeffrey NascimentoHartford$213K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
- Jordan PownerHartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.